Generics overtake new drugs in EU centralised procedure
This article was originally published in Scrip
One of the most striking statistics in the European Medicines Agency's first monthly report on the centralised approvals procedure is that generics have for the first time overtaken new products in terms of the number of applications for marketing authorisations dealt with by the agency. The report also reveals a sharp increase in the EMA's overall evaluation workload.
You may also be interested in...
EU and US regulators have opposing views when it comes to Merck's applications for a new indication and new dosing schedule for the company's successful PD-1 inhibitor Keytruda.
Regulators have pulled out all the stops in their efforts to get the Ebola vaccine to the marketing authorization stage in Africa.
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.